![FY 2022 Q1 Could Be the Last Hurrah for the COVID Earnings Surge](https://www.g2intelligence.com/wp-content/uploads/2022/05/June22.LIR_.EarningsReports2022.Q1-iStock-1800x1250-1-1080x675.jpg)
FY 2022 Q1 Could Be the Last Hurrah for the COVID Earnings Surge
Most diagnostics companies experienced modest, flat, or negative top-line revenue growth rates in the first quarter of 2022.
Most diagnostics companies experienced modest, flat, or negative top-line revenue growth rates in the first quarter of 2022.
Despite the emergence and rise of new Omicron variants, COVID-19 testing has declined as much as 90 percent, according to some reports.
Recent study suggests those being treated for acute conditions are likelier to schedule follow-up appointments after telehealth visits.
HHS will distribute OraSure’s InteliSwab COVID-19 rapid at-home antigen test kits to schools across the nation.
The FDA will almost certainly keep EUA tests on the market after the PHE expires.